CANF
OtherCan-Fite Biopharma Ltd
$3.35-0.15 (-4.29%)LIVE
Live · AMEX · May 9, Close
AI Insight
What's Moving CANF Today?
No stock-specific AI insight has been generated for CANF yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$7M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume83K
Avg Volume (10D)—
Shares Outstanding2.1M
CANF News
21 articles- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 MonthsYahoo Finance·Apr 30, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026Yahoo Finance·Mar 30, 2026
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer PatientYahoo Finance·Mar 26, 2026
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent AllowanceYahoo Finance·Mar 17, 2026
- CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer DataYahoo Finance·Mar 5, 2026
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsYahoo Finance·Mar 4, 2026
- Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer StudyYahoo Finance·Mar 4, 2026
- Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of NamodenosonYahoo Finance·Feb 17, 2026
- Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity TherapyYahoo Finance·Feb 9, 2026
- Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with NamodenosonYahoo Finance·Feb 5, 2026
- Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of NamodenosonYahoo Finance·Jan 20, 2026
- Sector Update: Health Care Stocks Edge Higher Late AfternoonYahoo Finance·Dec 26, 2025
- Sector Update: Health Care Stocks Lower in Friday Afternoon TradingYahoo Finance·Dec 26, 2025
- Top Midday Stories: Nvidia-Groq Licensing Deal; Target Attracts Growing Interest From Toms CapitalYahoo Finance·Dec 26, 2025
- Can-Fite Granted Brazilian Patent for Treatment of Sexual DysfunctionYahoo Finance·Dec 26, 2025
- Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio ChangeYahoo Finance·Dec 23, 2025
- Can-Fite Provides Update on Clinical and Financial StatusYahoo Finance·Dec 16, 2025
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceYahoo Finance·Nov 26, 2025
- Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 ConferenceYahoo Finance·Nov 24, 2025
- Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in BrazilYahoo Finance·Nov 20, 2025
All 21 articles loaded
Price Data
Open$2.98
Previous Close$3.50
Day High$3.01
Day Low$2.83
52 Week High—
52 Week Low—
Fundamentals
Market Cap$7M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume83K
Avg Volume (10D)—
Shares Outstanding2.1M
About Can-Fite Biopharma Ltd
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Company Details
Security TypeStock
ExchangeAMEX
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—